title: Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months.
abstract: BACKGROUND
  The aim of this study was to compare the outcome of 3 months vs. 18 months of amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the first episode of persistent AF.
  
  
  METHODS
  We included 51 patients who experienced the first episode of persistent AF receiving amiodarone (600 mg) daily for 4-6 weeks. If AF persisted, electrical cardioversion (ECV) was performed. All patients received amiodarone (200 mg daily) for 3 months and then were randomized to amiodarone (Group I) or placebo (Group II) and followed for 15 months. The control group comprised 9 untreated patients undergoing ECV. Treatment effectiveness was evaluated using a Bayesian model.
  
  
  RESULTS
  Eighteen months after AF reversion, 22 (81.5%) patients in Group I, 13 (54.2%) patients in Group II, and 1 (11.1%) patient in the control group remained in sinus rhythm. No differences were found between Group I patients who required ECV and Group II patients. Sinus rhythm was preserved in all Group I patients when it was achieved during amiodarone administration. Limiting adverse effects occurred in 3 (11.1%) patients in Group I.
  
  
  CONCLUSIONS
  In patients regaining sinus rhythm after the first episode of persistent AF, a 3-month amiodarone treatment after reversion is a reasonable option for rhythm control.
authors.affiliation: Hospital Ramos Mejia, Buenos Aires, Argentina. jorge.galperin@gmail.com.
authors.forename: Jorge
authors.initials: J
authors.lastname: Galperin
authors.forename: Marcelo V
authors.initials: MV
authors.lastname: Elizari
authors.forename: Ricardo
authors.initials: R
authors.lastname: Bonato
authors.forename: Raul
authors.initials: R
authors.lastname: Ledesma
authors.forename: Manuel
authors.initials: M
authors.lastname: Vazquez Blanco
authors.forename: Manuel
authors.initials: M
authors.lastname: Lago
authors.forename: Pablo
authors.initials: P
authors.lastname: Spada
authors.forename: Jorge
authors.initials: J
authors.lastname: Sanchez
authors.forename: Jorge
authors.initials: J
authors.lastname: Piasentin
authors.forename: Pablo A
authors.initials: PA
authors.lastname: Chiale
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000008:administration & dosage*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001118:Argentina; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D001499:Bayes Theorem; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D015150:Echocardiography, Doppler; D004554:Electric Countershock / Q000009:adverse effects; D015716:Electrocardiography, Ambulatory; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone